6533b85ffe1ef96bd12c1b98

RESEARCH PRODUCT

Multidimensional Prognostic Index and pro-adrenomedullin plasma levels as mortality risk predictors in older patients hospitalized with community-acquired pneumonia: a prospective study.

Massimiliano CopettiMario PlebaniMario Lo StortoMonica Maria MionJulia DaragjatiGiada BragatoAndrea FontanaAlberto PilottoManuela MioloPaolo CarraroMartina ZaninottoNicola VeroneseFilomena AddanteAlberto CellaSimone Dini

subject

0301 basic medicineMalemedicine.medical_specialtySeverity of Illness Index03 medical and health sciencesAdrenomedullin0302 clinical medicinePatient AdmissionOlder patientsCommunity-acquired pneumoniaPredictive Value of TestsRisk FactorsInternal medicineSeverity of illnessRisk of mortalityMedicineHumansProspective StudiesProtein PrecursorsProspective cohort studyGeriatric AssessmentAgedProportional Hazards ModelsAged 80 and overbusiness.industryProportional hazards modelGeneral MedicinePneumoniamedicine.diseasePrognosisPatient DischargeCommunity-Acquired InfectionsPneumonia030104 developmental biology030220 oncology & carcinogenesisPredictive value of testsFemalebusiness

description

BACKGROUND: To evaluate the prognostic accuracy of proadrenomedullin (proADM) in comparison with and in addition to the Multidimensional Prognostic Index (MPI), a validated predictive tool for mortality derived from a comprehensive geriatric assessment (CGA) to predict one-month mortality risk in older patients hospitalized with community-acquired pneumonia (CAP). METHODS: All patients aged 65 years and older, consecutively admitted to an acute geriatric ward with a diagnosis of CAP from February to July 2012. At admission and at discharge they were submitted to a standard CGA in order to calculate MPI. Moreover, plasma samples were taken at baseline and after one, three and five days of hospitalization for the analysis of pro-ADM. RESULTS: Fifty patients (mean age 86.2±7.5 years), with 31 at high risk of mortality (MPI-3) were enrolled. ProADM and MPI, both at admission and at discharge, were significant predictor of mortality. As expected, MPI at admission showed lower predictive accuracy than MPI at discharge (survival C-statistic 0.667 vs. 0.851). The addition of proADM to the MPI at admission significantly increased accuracy in predicting one-month mortality (C-statistics from 0.667 to 0.731, P=0.018 at baseline; from 0.667 to 0.733, P=0.008 at 1 day; from 0.633 to 0.724; P=0.019 at 3 days; from 0.667 to 0.828; P=0.003 at 5 days). Conversely, adding pro-ADM to the MPI at discharge did not significantly improve the model's prognostic accuracy. CONCLUSIONS: ProADM may significantly improve the prognostic accuracy of the MPI at admission in hospitalized elderly patients with CAP. © 2018 EDIZIONI MINERVA MEDICA.

10.23736/s0031-0808.18.03408-0https://pubmed.ncbi.nlm.nih.gov/29546738